SBTX Class Action: Learn About the Silverback Therapeutics Lawsuit  | Levi & Korsinsky, LLP

[ad_1]

Levi & Korsinsky, LLP announces that an SBTX class action lawsuit has been filed on behalf of investors who purchased Silverback Therapeutics, Inc.(SBTX) This lawsuit is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Silverback common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company’s initial public offering conducted on or about December 3, 2020, and/or (b) Silverback securities between December 3, 2020, and September 10, 2021, both dates inclusive. For more on the SBTX Lawsuit please contact us today.   

According to the Silverback Therapeuticslawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that:(i) Silverback’s lead product candidate SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumours, such as breast, gastric, and non-small cell lung cancers, was less effective than the Company had represented to investors; (ii) accordingly, the Company had overstated SBT6050’s commercial and/or clinical prospects; and (iii) as a result, the Offering Documents and Defendants’ public statements throughout the Class Period were materially false and/or misleading and failed to state information required to be stated therein.

TO LEARN MORE ABOUT THE SBTX CLASS ACTION LAWSUIT, CLICK HERE

 

If you suffered a loss in Silverback Therapeutics you have until January 4, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.  

Levi and Korsinsky

CONTACT: 


Levi & Korsinsky, LLP  

Joseph E. Levi, Esq.  

55 Broadway, 10th Floor  

New York, NY 10006  

jlevi@levikorsinsky.com  

Tel: (212) 363-7500  

Fax: (212) 363-7171  

www.zlk.com  

[ad_2]

Source link

You may also like...